Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Sanatoriumi Tsqaltubo | Healthcare Services | 35.6% | 93rd pct | 268 |
| Baiebi | Healthcare Services | 13.6% | 60th pct | 268 |
| Avtandil Qambarashvilis… | Healthcare Services | 5.1% | 35th pct | 268 |
| Kobuletis Sameditsino T… | Healthcare Services | -23.6% | 7th pct | 268 |
| New Clinic | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Kobuletis Sameditsino T… | Avtandil Qambarashvilis… | Sanatoriumi Tsqaltubo | Baiebi | New Clinic |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | -5.7% | 83.8% | 91.9% | 89.5% | — |
| EBITDA Margin | -23.6% | 5.1% | 35.6% | 13.6% | — |
| EBITDAR | -901 | 215 | 1,660 | 662 | — |
| EBITDAR Margin | -21.3% | 5.1% | 39.8% | 16.1% | — |
| EBIT Margin | -34.4% | 0.1% | 15.6% | 5.0% | — |
| Net Profit Margin | -34.5% | -2.3% | 0.2% | 3.1% | — |
| Operating Expense % of Sales | 17.9% | 78.7% | 56.3% | 75.9% | — |
| Returns | |||||
| Return on Assets (ROA) | -41.2% | -1.6% | 0.0% | 3.6% | — |
| Return on Equity (ROE) | -57.9% | -2.1% | 0.1% | 26.2% | — |
| ROIC [EBIT / Invested Capital] | |||||
| -59.8% |
| 0.1% |
| 4.0% |
| 7.1% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 11.7% | 50.1% | 69.7% | — |
| Debt-to-Equity | 0.00x | 0.16x | 1.09x | 5.08x | — |
| Debt-to-EBITDA | N/A | 3.36x | 5.66x | 4.40x | — |
| Equity-to-Assets | 71.1% | 74.7% | 46.0% | 13.7% | — |
| Net Debt | -83 | 720 | 8,379 | 2,379 | — |
| Cash & Equivalents | 83 | 2 | 20 | 74 | — |
| Total Debt | N/A | 722 | 8,399 | 2,453 | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.97x | 2.08x | 0.95x | 0.52x | — |
| Quick Ratio | 0.97x | 2.08x | 0.95x | 0.36x | — |
| Cash Ratio | 0.09x | 0.00x | 0.03x | 0.36x | — |
| Total Current Assets | 899 | 1,292 | 644 | 108 | — |
| Total Current Liabilities | 925 | 622 | 678 | 207 | — |
| Inventory | N/A | N/A | N/A | 34 | — |
| Trade Receivables | 788 | 1,292 | 544 | 356 | — |
| Trade Payables | 289 | 622 | 444 | 373 | — |
| Net Working Capital | -25 | 670 | -34 | -99 | — |
| Net Working Capital % of Revenue | -0.6% | 16.0% | -0.8% | -2.4% | — |
| Trade Working Capital | 499 | 670 | 100 | 17 | — |
| Trade Working Capital % of Revenue | 11.8% | 16.0% | 2.4% | 0.4% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | 12.79x | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | 28.5 | — |
| Receivables Turnover | 5.38x | 3.25x | 7.66x | 11.54x | — |
| Days Sales Outstanding (DSO) | 67.8 | 112.3 | 47.6 | 31.6 | — |
| Payables Turnover | 15.50x | 1.09x | 0.76x | 1.16x | — |
| Days Payable Outstanding (DPO) | 23.6 | 334.5 | 477.8 | 315.5 | — |
| Cash Conversion Cycle | 44.3 days | -222.3 days | -430.2 days | -255.3 days | — |
| Asset Turnover | 1.19x | 0.68x | 0.25x | 1.17x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | N/A | 748 | 27 | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | -9 | 27 | — |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 50.4% | 4.9% | — |
| Dividends Declared | N/A | N/A | N/A | 0 | — |
| Dividend Payout Ratio | N/A | N/A | N/A | 0.0% | — |